BioWorld

April 27, 2004

View Archived Issues

Tarceva Trial Proves Positive, Pushes OSI, Genentech Stocks

Investors adored results from a Phase III trial of an experimental cancer drug, significantly driving up stock prices of two of the companies involved in its development. (BioWorld Today) Read More

CV Therapeutics Begins Second Phase III Trial Of Regadenoson

Read More

Antisoma's Stock Falls On Phase III Miss With R1549

Read More

BioWorld Biotechnology State of the Industry Report 2004 now available

Read More

Advancing Three Cancer Drugs, Salmedix Takes Aim At $86M IPO

Read More

Other News To Note

Read More